Cytek Biosciences vs Harvard Bioscience
CTKB and HBIO side by side, both in laboratory apparatus and analytical, optical, measuring, and controlling instruments. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CTKB and HBIO compare
Cytek Biosciences is the larger company, worth 18 times as much as Harvard Bioscience ($759M against $42.7M).
Cytek Biosciences grew revenue faster over the last twelve months (5.5% versus 2.3% for Harvard Bioscience).
Harvard Bioscience keeps more of each dollar of sales as profit, with a net margin of −13.2% compared with −39.1% at Cytek Biosciences.
Cytek Biosciences scores higher on the StockData Score (8 against 3 for Harvard Bioscience), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CTKB | HBIO |
|---|---|---|
| Size and price | ||
| Market cap | $759M | $42.7M |
| Share price | $5.84 | $9.39 |
| Change, 1 year | 21.4% | 50.9% |
| Change, 5 years | −70.0% | −87.4% |
| Beta (5Y) | 1.10 | 1.39 |
| Employees | 702 | 339 |
| StockData Score | ||
| Total score | 8 (better) | 3 |
| Valuation score | 2 (better) | 0 |
| Growth score | 1 | 1 |
| Performance score | 0 | 1 (better) |
| Health score | 5 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 3.7× | 0.5× (better) |
| P/B | 2.4× (better) | 8.4× |
| FCF yield | −1.8% (better) | −7.4% |
| Fair value | $6.36 | – |
| Margin of safety | 8.2% | – |
| Growth | ||
| Revenue growth (TTM) | 5.5% (better) | 2.3% |
| Revenue growth, 5Y average | 209% (better) | −3.3% |
| Profitability | ||
| Gross margin | 54.7% | 57.4% (better) |
| Operating margin | −21.1% | −1.8% (better) |
| Net margin | −39.1% | −13.2% (better) |
| FCF margin | −6.5% | −3.5% (better) |
| Return on equity | −23.2% (better) | −123% |
| Return on invested capital | −12.8% | −5.6% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 7.28 (better) |
| Interest coverage | −562.6× | – |
| Current ratio | 4.46 (better) | 1.76 |
| Altman Z-score | 4.15 (better) | −2.36 |
| Piotroski F-score | 3 | 3 |
| Dividends and buybacks | ||
| Buyback yield | −0.00% | – |
| Shareholder yield | −0.00% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 62.7% | 36.9% |
| Held by insiders | 10.6% | – |
| Insider net buying, 12 months | – | $202K |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 3.5% | – |
Go deeper
- CTKB stock overview
- CTKB income statement
- CTKB valuation and score
- HBIO stock overview
- HBIO income statement
- HBIO valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.